-
Piper Jaffray Defends Alder Despite Stock Slump, Looks To What's Next In Migraine Management
Tuesday, June 27, 2017 - 12:11pm | 606Read More...Shares of Alder Biopharmaceuticals Inc (NASDAQ: ALDR) lost more than 20 percent on Tuesday and hit a new 52-week low of $13.80 despite reporting positive results for its late-stage migraine prevention drug called eptinezumab. Eptinezumab was successful in meeting the primary and key secondary...
-
Big Biotech In The Earnings Spotlight
Tuesday, April 26, 2016 - 8:08am | 735Read More...The three largest biotechs are set to share their latest quarterly results this week. Wall Street analysts are looking for solid to strong growth from all three. However, expectations are lower for many other biotech and pharmaceutical companies reporting this week. The three largest public...
-
Alder Biopharma Surged 60% Following Phase 2 Results
Monday, March 28, 2016 - 11:15am | 272Read More...Shares of Alder Biopharmaceuticals Inc (NASDAQ: ALDR), a clinical-stage biopharmaceutical company, surged higher by nearly 60 percent on Monday. Alder Biopharmaceuticals announced earlier in the morning positive top-line data from 2 clinical trials which studied its ALD403 product, an antibody...
